These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 36430263)

  • 1. Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas.
    Albarrán V; Villamayor ML; Chamorro J; Rosero DI; Pozas J; San Román M; Calvo JC; Pérez de Aguado P; Moreno J; Guerrero P; González C; García de Quevedo C; Álvarez-Ballesteros P; Vaz MÁ
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas.
    Sethi TK; Keedy VL
    Curr Treat Options Oncol; 2016 Feb; 17(2):11. PubMed ID: 26931561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabozantinib as an emerging treatment for sarcoma.
    Schöffski P; Blay JY; Ray-Coquard I
    Curr Opin Oncol; 2020 Jul; 32(4):321-331. PubMed ID: 32541320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regorafenib for the Treatment of Sarcoma.
    Blay JY; Duffaud F; George S; Maki RG; Penel N
    Curr Treat Options Oncol; 2022 Nov; 23(11):1477-1502. PubMed ID: 36178573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study.
    Liu Z; Gao S; Zhu L; Wang J; Zhang P; Li P; Zhang F; Yao W
    Cancer Med; 2021 Nov; 10(21):7593-7600. PubMed ID: 34564939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?
    Tian Z; Niu X; Yao W
    Front Oncol; 2020; 10():1642. PubMed ID: 32984034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing's Sarcoma and Chondrosarcoma.
    Giordano G; Merlini A; Ferrero G; Mesiano G; Fiorino E; Brusco S; Centomo ML; Leuci V; D'Ambrosio L; Aglietta M; Sangiolo D; Grignani G; Pignochino Y
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial.
    Italiano A; Mir O; Mathoulin-Pelissier S; Penel N; Piperno-Neumann S; Bompas E; Chevreau C; Duffaud F; Entz-Werlé N; Saada E; Ray-Coquard I; Lervat C; Gaspar N; Marec-Berard P; Pacquement H; Wright J; Toulmonde M; Bessede A; Crombe A; Kind M; Bellera C; Blay JY
    Lancet Oncol; 2020 Mar; 21(3):446-455. PubMed ID: 32078813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma.
    Fleuren EDG; Vlenterie M; van der Graaf WTA
    Front Oncol; 2023; 13():1013359. PubMed ID: 36994209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world experience of tyrosine kinase inhibitors in children, adolescents and adults with relapsed or refractory bone tumours: A Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) study.
    Peretz Soroka H; Vora T; Noujaim J; Marcoux N; Cohen-Gogo S; Alcindor T; Holloway C; Rodrigues C; Karachiwala H; Alvi S; Lee U; Cheng S; Banerji S; Oberoi S; Feng X; Smrke A; Simmons C; Razak AA; Gupta AA
    Cancer Med; 2023 Sep; 12(18):18872-18881. PubMed ID: 37724607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor tyrosine kinase inhibitors for the treatment of osteosarcoma and Ewing sarcoma.
    Just MA; Van Mater D; Wagner LM
    Pediatr Blood Cancer; 2021 Aug; 68(8):e29084. PubMed ID: 33894051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma).
    Anderson P; Kopp L; Anderson N; Cornelius K; Herzog C; Hughes D; Huh W
    Expert Opin Investig Drugs; 2008 Nov; 17(11):1703-15. PubMed ID: 18922107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of bone and soft-tissue sarcomas registered during the year 2012 at Tata Memorial Hospital, Mumbai, with clinical outcomes.
    Bajpai J; Khanna N; Vora T; Gulia A; Laskar S; Puri A; Sanduptla B; Chinnaswamy G; Nayak P; Juvekar SL; Janu A; Desai S; Ghosh J; Purandare N; Ramadwar M; Rangarajan V; Rekhi B
    Indian J Cancer; 2018; 55(1):37-44. PubMed ID: 30147091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: current hurdles and future perspectives.
    Fleuren ED; Versleijen-Jonkers YM; Boerman OC; van der Graaf WT
    Biochim Biophys Acta; 2014 Apr; 1845(2):266-76. PubMed ID: 24582852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical signaling pathways in bone sarcoma: candidates for therapeutic interventions.
    Geryk-Hall M; Hughes DP
    Curr Oncol Rep; 2009 Nov; 11(6):446-53. PubMed ID: 19840522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apatinib for advanced sarcoma: results from multiple institutions' off-label use in China.
    Xie L; Guo W; Wang Y; Yan T; Ji T; Xu J
    BMC Cancer; 2018 Apr; 18(1):396. PubMed ID: 29625604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 'other' bone sarcomas in Japan: a retrospective study of primary bone sarcomas other than osteosarcoma, Ewing sarcoma and chondrosarcoma, using data from the Bone Tumuor Registry in Japan.
    Nagano A; Tsugita M; Nishimoto Y; Akiyama H; Kawai A
    Jpn J Clin Oncol; 2021 Aug; 51(9):1430-1436. PubMed ID: 34105731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
    Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
    Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself.
    Yang QK; Chen T; Wang SQ; Zhang XJ; Yao ZX
    Angiogenesis; 2020 Aug; 23(3):279-298. PubMed ID: 32333216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.
    Duffaud F; Mir O; Boudou-Rouquette P; Piperno-Neumann S; Penel N; Bompas E; Delcambre C; Kalbacher E; Italiano A; Collard O; Chevreau C; Saada E; Isambert N; Delaye J; Schiffler C; Bouvier C; Vidal V; Chabaud S; Blay JY;
    Lancet Oncol; 2019 Jan; 20(1):120-133. PubMed ID: 30477937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.